NSCLC still has a poor prognosis, and immunotherapy (IMT) has become part of the treatment of patients with no driver alterations (epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK)) (41). This evidence concerns the gene EGFR and non-small cell lung carcinoma.